Monte Rosa Therapeutics Inc — Quarterly Cash Flow (NASDAQ:GLUE) | MetaTrader

Open full chart

Financials

Overview Estratto Conto Statistics Dividends

Quarterly Annual

Total assets 315.08 M438.73 M393.2 M359.59 M459.84 M Total liabilities 109.62 M215.8 M118.04 M91.51 M214 M Total equity 205.46 M222.94 M275.16 M268.08 M245.84 M Total liabilities & shareholders' equities 315.08 M438.73 M393.2 M359.59 M459.84 M Total debt ————— Net debt —————

Notizie

Le azioni Monte Rosa salgono sui risultati dello studio sul cancro alla prostata

Monte Rosa shares rise on prostate cancer trial results

Monte Rosa riporta dati positivi da trial su farmaco per cancro alla prostata

Monte Rosa reports positive trial data for prostate cancer drug

NeoGenomics (NEO) Q4 Earnings and Revenues Surpass Estimates

Target di prezzo per le azioni Monte Rosa alzato a $37 da $27,50 da Piper Sandler

Monte Rosa stock price target raised to $37 from $27.50 at Piper Sandler

Monte Rosa Therapeutics fissa il prezzo dell’offerta pubblica a 300 milioni di dollari

Monte Rosa Therapeutics prices $300 million public offering

GLUE Stock Up 45% on Positive Interim Data on Inflammation Drug

Monte Rosa Therapeutics (GLUE) is on the Move, Here's Why the Trend Could be Sustainable

Wall Street incerta, settore della difesa ancora sotto i riflettori